Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
2-5A also potently elevated RNA for macrophage inhibitory cytokine-1/nonsteroidal antiinflammatory drug-activated gene-1, a TGF-beta superfamily member implicated as an apoptotic suppressor of prostate cancer.
|
16203993 |
2005 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is also demonstrated that GTN modulates the level of expression of clusterin (CLU) which is dependent of GDF‑15, two markers associated with docetaxel resistance in prostate cancer.
|
30720069 |
2019 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined whether sequence variants in the MIC-1 gene are associated with the risk of prostate cancer.
|
15316060 |
2004 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The augmented expression of MIC-1 in PC compared to BPH and HC subjects is in concurrent of the over-expression of MIC-1 in PC reports and confiscates the contradictory findings of other studies.
|
29203798 |
2017 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further, they provide a functional basis to understand GDF15 as a biomarker of poor prognosis and a candidate therapeutic target in prostate cancer.
|
24780757 |
2014 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Examination of sera from individuals with advanced prostate cancer showed a direct relationship between MIC-1 abundance and cancer-associated weight loss.
|
17982462 |
2007 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of MIC-1 on prostate cancer bone metastases are unknown.
|
19152406 |
2009 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, our findings show that MIC-1 has a role in prostate cancer metastasis, in part, by promoting the motility of these cells.
|
19946339 |
2010 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the role GDF15 plays in tumorigenesis of prostate carcinoma PC-3 cells.
|
22872134 |
2012 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
NSAID inhibition of prostate cancer cell migration is mediated by Nag-1 Induction via the p38 MAPK-p75(NTR) pathway.
|
21097678 |
2010 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A connection between GDF15 and body-weight regulation was initially suggested on the basis of an observation that increasing GDF15 levels in serum correlated with weight loss in individuals with advanced prostate cancer.
|
28846098 |
2017 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since most, if not all, of these pathways have been implicated in prostate cancer progression, suppressing their activities by inducing GDF15 is consistent with the anticancer effects of MSA in prostate cancer.
|
31539407 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these events led to a dramatic increase in processing of the progrowth differentiation factor pro-GDF15 as the first PACE4 substrate to be identified in prostate cancer.
|
28993410 |
2017 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SNPs of CD44 (rs9666607), ABCC1 (rs35605 and rs212091) and GDF15 (rs1058587) were associated with PCa survival and predicted to be functional.
|
29726910 |
2018 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of the MIC-1 gene in prostate cancer is significantly higher than in noncancerous tissues, especially in more aggressive forms of the disease (Gleason score>5).
|
12671711 |
2003 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, in prostate cancer, CtBP1-regulated miR-34a modulates STMN1 expression and is involved in cancer progression through the CtBP1miR-34aSTMN1GDF15 axis.<b>Implications:</b> The CtBP1miR-34aSTMN1GDF15 axis is a potential therapeutic target for treatment of aggressive prostate cancer.<i></i>.
|
29025958 |
2018 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diet-induced macrophage inhibitory cytokine 1 promotes prostate cancer progression.
|
24344250 |
2014 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is the first study to show that altered NPY and MIC-1 expression are significantly associated with prostate cancer progression and suggests that these molecules be developed further as biomarkers in the management of prostate disease.
|
16614113 |
2006 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We discuss studies that focus on the regulation of GDF-15 expression and its role in tissue homeostasis, repair and the immune response with an emphasis on the role in PCa development.
|
22370725 |
2012 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the current study, the regulation and role of NAG-1 expression in PC-3 human prostate carcinoma cells by VES was examined.
|
18413810 |
2008 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Transgenic mice expressing human NAG-1 are resistant to intestinal and prostate cancer, suggesting that NAG-1 is a tumor suppressor.
|
23261467 |
2013 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The data supports our hypothesis that GDF15 plays a role in the early stages of human prostate cancer.
|
17286605 |
2007 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of EGR1 expression in PCa cells revealed it was required for the OCy-derived GDF15-mediated induction of in vitro PCa cell proliferation, migration and invasion.
|
30755731 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present findings may be helpful in elucidating the anticancer mechanisms of GLP through NAG-1 induction for its chemopreventive potential in PCa.
|
30272272 |
2018 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human prostate cancer DU145 cells expressing the H6D NAG-1 or wild-type (WT) NAG-1 were injected subcutaneously into nude mice and tumor growth was monitored.
|
21809352 |
2012 |